Highlights

Delivering a strong recovery in first-half Group operating performance with a return to pre-pandemic level revenues at all three divisions

• Group revenue up 12% driven by strong recovery in patient volumes which exceeded pre-pandemic levels at Hirslanden and Mediclinic Middle East
• Material improvement in Group EBITDA margin to 15.8% (1H21: 12.1%); returning towards pre-pandemic levels (1H20: 16.6%)
• Financial position and liquidity strengthened; Group cash conversion strong at 104% (1H21: 42%)

Ongoing strategic execution, navigating the pandemic and adapting to changing client needs

• Continuing to effectively navigate the pandemic
• Further expanding across the continuum of care to deliver future growth opportunities
• Progressing digital initiatives to enhance patient pathways and deliver seamless integrated care

Positioned well for future growth, including increased revenue guidance for the full-year

• Strong first-half performance positions the Group well heading into the second half of the year
• Upward revision to FY22 revenue guidance for all three divisions; margin guidance remains unchanged
• Key priority to return to pre-pandemic profitability at all three divisions over time